Novasep Invests $11.8 Million in Fill/Finish for Low-Volume BiologicsBy
Novasep, a Lyon, France-headquartered contract manufacturer and life-science service provider, has invested EUR 10 million ($11.8 million) in a commercial fill/finish facility for viral vectors, monoclonal antibodies (mAbs), and other low-volume biologics. The facility will be located in Seneffe, Belgium and will be operational in the second half of 2019.
The new plant will feature a fill/finish suite with filling equipment and isolators. It will deliver up to 10,000 vials per session with two to three sessions per week.
This project is part of Novasep’s recent investments in biologics-related production. The company is investing EUR 27-million ($32-million) in a new commercial-scale viral-vector production facility in Seneffe that is scheduled to be fully qualified by the first quarter of 2019. It is also investing EUR 17-million ($20-million) in a cGMP clinical-scale mAb production facility in Pompey, France and which is scheduled to be commissioned in the second half of 2019.